Sanjivani Paranteral Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3seat82u0nr8kf9onxu1mhnh.pdf

Key Takeaways


Revenue Growth & Geographic Expansion


Margin Dynamics & New Product Impact

Srivardhan: "When we add new products, the cost efficiencies of those products are not there. The more we streamline the supply chain of those new products, we are able to get a better margin out of those products. Since we are adding new products rapidly, the margin seems to be declining."

Segment Trends: Injectables vs. Oral Solids

Srivardhan: "we are facing a lot of stiff competition in the market that we are present in. And there is a lot of pricing pressure as well. We see that there have been a lot of new factories that have opened up in the past two years when the COVID had relaxed the regulations and registration guidelines."

Facility Upgrades & Regulatory Approvals

Ashwani Khemka: "But due to this Red Sea embargo and the delays in shipments to the equipment's to Prague, the things got delayed and people could not travel."

HAL Joint Venture & Management Expansion

Ashwani Khemka: "as committed that we are going to start in the month of October 2024, it will be strictly on that deadline and maybe 15-20 days before that also."

Pushback & Unanswered Questions


Guidance & Commitments

CommitmentSpecificsTimeline
Other expense normalizationExpenses from new product development, JV setup, and late commissions to come downNext quarter (Q4 FY24)
Oral solid segment normalizationRecovery from current competition and pricing pressureTwo to three quarters
Francophone Africa entryLaunch with agents, distributors, and selected productsApril 2024 (Q1 FY25)
Prague packaging line operationalDelayed by Red Sea embargo; now opening late March25th or 26th of March 2024
Dehradun Latin country inspectionFacility upgradation and regulatory inspectionEnd of March / first week of April 2024
Dehradun cascade approvalsAutomatic approval in 3–4 Latin countries after first approval; East European country triggerLatin: post-inspection; East Europe: year-end 2024
HAL JV start of operationsConstruction starting, machines arriving June–JulyOctober 2024, possibly 15–20 days earlier
HAL revenue commencementFirst revenue from the JVQ4 FY24
Segment margin disclosureManagement to revisit disclosing margins across three segmentsTwo to three quarters

Key Metrics

MetricQ3 FY24
Revenue₹14.96 cr, +64% YoY
EBITDA margin13.1%, +298 bps YoY from 10.1%
Net profit₹1.65 cr, +73% YoY
PAT margin11%, +59 bps YoY from 10.4%
9M FY24 revenue₹41.55 cr, +52% YoY
9M FY24 EBITDA₹6.08 cr, +44% YoY
9M FY24 EBITDA margin14.6%, -80 bps YoY from 15.4%
9M FY24 PAT margin11.8%, -100 bps YoY from 12.8%
Injectables revenue growth+89% YoY
Nutraceuticals revenue growth+27% YoY
Revenue mix35.2% domestic, 64.8% exports
CMO sales~11% of revenue
Capacity utilization, injectables70%
Capacity utilization, orals35%
HAL JV total capex₹35–38 cr, ~10% invested so far
Total capex across all projects~₹31 cr, ₹5 cr already invested